Vortioxetine

CAS: 508233-74-7
Molecular Formula: C18H22N2S
Molecular Weight: 298.44568
Product description:1) in healthy volunteers as the subjects of different experimental study, walter for paxil respectively with CYP2D6 inhibitors bupropion (bupropion), CYP2C9 CYP2C19 / CYP3A inhibitors fluconazole (fluconazole) or CYP3A/permeability glycoprotein (p - gp) inhibitors ketone health zun (ketoconazole), walter for paxil bioavailability will increase, so when walter for paxil and strong CYP2D6 inhibitors (such as bupropion, fluoxetine and paroxetine, quinidine) share, the dose should be cut in half. (2) walter for paxil and strong CYP inducers (rifampicin) used, its bioavailability less, so when walter for paxil and rifampicin or other strong CYP inducers (e.g., carbamazepine, phenytoin sodium) share, should increase the drug doses, but the maximum dose should not be higher than normal dose of 3 times. (3) in addition, the use of 5 - HT drugs itself is the cause of abnormal bleeding risk factors, so when walter for paxil and aspirin and non-steroidal anti-inflammatory drugs or other medicines affect blood clotting